日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Integrated Multi-omic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer

整合多组学分析鉴定出 BRD8/EP400 是介导 HR+/HER2+ 乳腺癌抗 HER2 反应的关键染色质模块

Gao, Ang; Khatri, Parth H; Ma, Gui; Liu, Peng; Fernandez-Martinez, Aranzazu; Donahue, Kristine; Wang, Yidan; Kim, Eui-Jun; Hu, Mingshan; Liu, Fabao; Zhou, Jingjing; Chan, Ngai Ting; Yang, Xingjian; Welch Schwartz, Rene; Ong, Irene M; Burkard, Mark E; Wisinski, Kari B; Perou, Charles M; Dinh, Huy Q; Xu, Wei

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)

Talimogene laherparepvec 和 atezolizumab 在新辅助化疗后 HER2 阴性乳腺癌中的应用:一项机会窗口 II 期试验 (SOLTI-1503 PROMETEO)

Pascual, Tomás; Vidal, Maria; Cejalvo, Juan M; Vega, Estela; Sanfeliu, Esther; Villacampa, Guillermo; Ganau, Sergi; Parreño, Ana María Julve; Zamora, Esther; Miranda, Ignacio; Delgado, Ana; Bermejo, Begoña; Seguí, Elia; Brasó-Maristanty, Fara; de la Cruz-Merino, Luis; Juan, Manel; Galván, Patricia; Gonzàlez-Farré, Xavier; Chillara, Samyukta; Villagrasa, Patricia; Pfefferle, Adam D; O'Connell, Constandina E; Ferrero-Cafiero, Juan M; Oliveira, Mafalda; Perou, Charles M; Prat, Aleix

Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trial

新辅助帕博西尼联合内分泌治疗与化疗治疗ER+/HER2-乳腺癌:一项随机II期试验

Matikas, Alexios; Tzoras, Evangelos; Sarafidis, Michail; Sifakis, Emmanouil G; Bjöhle, Judith; Barnekow, Elin; Margolin, Sara; Isaksson-Friman, Erika; Kessler, Luisa Edman; Zouzos, Athanasios; Johansson, Hemming; Hellström, Mats; Agartz, Susanne; Grybäck, Per; Salgkamis, Dimitrios; Zerdes, Ioannis; Wang, Kang; Hartman, Johan; Acs, Balazs; Sun, Wenwen; Boyaci, Ceren; Villacampa, Guillermo; Pascual, Tomas; Gavila, Joaquin; Prat, Aleix; Perou, Charles; Brandberg, Yvonne; Bergh, Jonas; Hatschek, Thomas; Foukakis, Theodoros

Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.

抗 CSF-1R 疗法与免疫化疗相结合,可协调适应性免疫反应,以消除富含巨噬细胞的三阴性乳腺癌。

Pedroza Diego A, Yuan Xueying, Liu Fengshuo, Chan Hilda L, Zhang Christina, Bowie William, Smith Alex J, Calderon Sebastian J, Lieu Nadia, Wu Weiguo, Porter Paul, Sarkar Poonam, Zhao Na, Oehler Constanze V, Peller Ondrej, Gaber M Waleed, Zhu Qian, Perou Charles M, Zhang Xiang H-F, Rosen Jeffrey M

Identifying Locally Recurrent Versus Second Primary Breast Cancer: Genomic Versus Clinical Criteria from Carolina Breast Cancer Study Phase III

区分局部复发性乳腺癌和第二原发性乳腺癌:来自卡罗莱纳乳腺癌研究III期的基因组标准与临床标准

Van Alsten, Sarah C; Love, Michael I; Calhoun, Benjamin C; Butler, Eboneé N; Pfefferle, Adam D; Kirk, Erin L; Halloran, Christopher S; Zipple, Isaiah W; Perou, Charles M; Carey, Lisa A; Hoadley, Katherine A; Troester, Melissa A

Proteotranscriptomic Dissection of Breast Cancer T Cell States Identifies CD103+ Tfh-derived Cytotoxic Cells Linked to Immunotherapy Response

乳腺癌T细胞状态的蛋白质转录组学分析鉴定出与免疫治疗反应相关的CD103+ Tfh衍生细胞毒性细胞

Al-Eryani, Ghamdan; Van Der Leij, Sophie; Masle-Farquhar, Etienne; Chan, Chia-Ling; Harvey, Kate; Wu, Sunny Z; Roden, Dan; Wang, Taopeng; Reeves, John; Yeung, Bertrand Z; Goodnow, Christopher C; Ma, Cindy S; Perou, Charles M; Hacohen, Nir; Al'Khafaji, Aziz M; Nilsson, Mats; Lundeberg, Joakim; Batten, Marcel; Junankar, Simon; Swarbrick, Alexander

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9(+) monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancer.

MERTK 抑制剂与免疫调节剂环磷酰胺协同作用,可诱导 CXCL9(+) 单核细胞-巨噬细胞编程,并在三阴性乳腺癌中产生持久的抗肿瘤免疫力。

Smith Alex J, Schrank Zachary, Guan Nan, Pedroza Diego A, Calderon Sebastian, Yuan Xueying, Zhao Na, Gabriel Zoe, Gao Yang, Rivas Charlotte, Liu Fengshuo, Serody Jonathan S, Perou Charles M, Earp H Shelton, Rosen Jeffrey M

Genomic Analysis Reveals Racial and Age-Related Differences in the Somatic Landscape of Breast Cancer and the Association with Socioeconomic Factors

基因组分析揭示乳腺癌体细胞图谱中存在的种族和年龄差异及其与社会经济因素的关联

Van Alsten, Sarah C; Love, Michael I; Calhoun, Benjamin C; Butler, Eboneé N; Perou, Charles M; Hoadley, Katherine A; Troester, Melissa A

HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy

HER2DX 在老年 HER2 阳性早期乳腺癌患者中的应用:曲妥珠单抗±化疗 RESPECT 试验的长期随访结果

Nozawa, Kazuki; Sawaki, Masataka; Uemura, Yukari; Tsuneizumi, Michiko; Takano, Toshimi; Gondo, Naomi; Hara, Fumikata; Harao, Michiko; Toyama, Tatsuya; Taira, Naruto; Vivancos, Ana; Perou, Charles M; Sanfeliu, Esther; Brasó-Maristany, Fara; Parker, Joel S; Buckingham, Wesley; Paré, Laia; Villacampa, Guillermo; Marín-Aguilera, Mercedes; Villagrasa, Patricia; Prat, Aleix; Iwata, Hiroji

Corrigendum to "Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy" [Biomaterials 312 (2025) 122750

更正“纳米制剂TLR 7/8激动剂和PI3Kδ抑制剂对肿瘤微环境的免疫调节增强了放射疗法的治疗效果”[Biomaterials 312 (2025) 122750]

Yazdimamaghani, Mostafa; Kolupaev, Oleg V; Lim, Chaemin; Hwang, Duhyeong; Laurie, Sonia J; Perou, Charles M; Kabanov, Alexander V; Serody, Jonathan S